Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Net Margin (2016 - 2025)

IGC Pharma (IGC) has disclosed Net Margin for 16 consecutive years, with 953.4% as the latest value for Q3 2025.

  • Quarterly Net Margin fell 53666.0% to 953.4% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 582.82% through Sep 2025, up 47965.0% year-over-year, with the annual reading at 560.27% for FY2025, 40628.0% up from the prior year.
  • Net Margin for Q3 2025 was 953.4% at IGC Pharma, down from 487.5% in the prior quarter.
  • The five-year high for Net Margin was 362.73% in Q1 2025, with the low at 7757.14% in Q3 2021.
  • Average Net Margin over 5 years is 1847.1%, with a median of 977.97% recorded in 2024.
  • Peak annual rise in Net Margin hit 723512bps in 2021, while the deepest fall reached -643154bps in 2021.
  • Over 5 years, Net Margin stood at 1676.76% in 2021, then skyrocketed by 60bps to 677.41% in 2022, then plummeted by -304bps to 2739.71% in 2023, then surged by 74bps to 711.67% in 2024, then crashed by -34bps to 953.4% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 953.4%, 487.5%, and 362.73% for Q3 2025, Q2 2025, and Q1 2025 respectively.